Publications 2007

1 When should antiretroviral therapy for HIV be started? AN Phillips, BG Gazzard, N Clumeck, MH Losso, JD Lundgren. Editorial
BMJ 2007;334;76-78 article

2 Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. C Holkmann Olsen, A Mocroft, O Kirk, S Vella, A Blaxhult, N Clumeck, M Fisher, C Katlama, AN Phillips and JD Lundgren for the EuroSIDA study group.
HIV Med. 2007;8;96-104 abstract

3 Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. Writing committee: N Friis-Møller, P Reiss, CA Sabin, R Weber, A D´Arminio Monforte, W El-Sadr, R Thiebaut, S de Wit, O Kirk, E Fontas, MG Law, A Phillips, JD Lundgren on behalf of the D:A:D study group.
N Engl J Med. 2007 April 26;356:1723-35 abstract

4 Evolution of drug resistance in HIV infected patients remaining on a virologically failing cART regimen. A Cozzi-Lepri, AN Phillips, L Ruiz, B Clotet, C Loveday, J Kjær, H Mens, N Clumeck, L Viksna, F Antunes, L Machala, JD Lundgren.
AIDS. 2007 Mar 30;21(6):731-32 abstract

5 Chronic renal failure among HIV-1-infected patients. A Mocroft, O Kirk, J Gatell, P Reiss, P Gargalianos, K Zilmer, M Beniowski, J-P Viard, S Staszewski, and JD Lundgren for the EuroSIDA study group.
AIDS. 2007 May 31, 21(9):1119-1127 abstract

6 Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. The Antiretroviral Therapy (ART) Cohort Collaboration. Writing committee:M May, JAC Sterne, C Sabin, D Costagliola, AC Justice, R Thiebaut, J Gil, A Phillips, P Reiss, R Hogg, B Ledergerber, A D´arminio Monforte, N Schmeisser, S Staszewski, M Egger.
AIDS. 2007 May 31, 21(9):1185-1197 abstract

7 Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection. H Larsen, M-L von Linstow, B Lundgren, B Hogh, H Westh, JD Lundgren.
Emerg Infect Dis. 2007 Jan;13(1):66-72 abstract

8 Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2. The ESPRIT Research Group; Z Fox, F Antunes, R Davey, B Gazzard, N Klimas, A Labriola, M Losso, JD Neaton, AN Phillips,  K Ruxrungtham, S Staszewski, L Weiss, JD Lundgren.
HIV Med. 2007 Mar;8(2):112-23  abstract

9 Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, M Losso, A Lazzarin, JD Lundgren for the EuroSIDA study group.
Lancet. 2007 July 19, online. Lancet. 2007 Aug 4;370(9585):407-13 abstract 

10 A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. M May, JAC Sterne, M Shipley, E Brunner, R d'Agostino, P Whincup, Y Ben-Shlomo, A Carr, B Ledergerber, JD Lundgren, AN Phillips, J Massaro, M Egger.
Int J Epidemiol. 2007, 25 July, online; doi:10.1093/ije/dym135 abstract

11  Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy : The EuroSIDA risk-score. A Mocroft, B Ledergerber, K Zilmer, O Kirk, JP Viard, P Reiss, A Lazzarin, L Machala, AN Phillips, JD Lundgren for the EuroSIDA study group.
AIDS. 2007 Sep;21(14):1867-1875.  abstract

12 Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced HIV-infected patients with high and low CD4 counts. A Mocroft, S Staszewski, R Weber, J Gatell, J Rockstroh, J Gasiorowski, G Panos, A d’Arminio Monforte, A Rakhmanova, AN Phillips, JD Lundgren
Antivir Ther. 2007;12(3):325-33. Erratum in: Antivir Ther. 2007;12(4):577 abstract

13 Current haemoglobin levels are more predictive of disease progression than haemoglobin measured at baseline in patients receiving antiretroviral tratment for HIV-1 infection. JD Kowalska, A Mocroft, A Blaxhult, R Colebunders, J van Lunzen, D Podlekareva, A-BE Hansen, L Machala, I Yust and T Benfield for the EuroSIDA Study Group.
AIDS Res Hum Ret. 2007; 23 (10): 1183-1188 abstract

14 Clinical outcomes in clinical trials of anti-HIV treatment. J Reekie, A Mocroft, J Neaton and JD Lundgren.
Future HIV Ther. 2007 1(3), 251-258 abstract

15 Risk of cancers during interrupted antiretroviral therapy in the SMART study. MJ Silverberg, J Neuhaus, M Bower, D Gey, A Hatzakis, K Henry, J Hidalgo, L Lourtau, JD Neaton, G Tambussi, and DI Abrams.
AIDS. 2007, 21:1957-1963 abstract

16 Meta-analysis of procalcitonin for sepsis detection. JU Jensen, B Lundgren, JD Lundgren.
Lancet Infect Dis. 2007 Aug; 7(8):499-500 abstract

17 Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue based regimens in ART-naïve and experienced patients. F Ceccherini-Silberstein, A Cozzi-Lepri, L Ruiz, A Mocroft, AN Phillips, C Holkmann-Olsen, JM Gatell, FH Günthard, P Reiss, CF Perno, B Clotet, and JD Lundgren for the EuroSIDA study group.
J Infect Dis. 2007 Oct 15;196(8):1180-90. Epub 2007 Sep 19. abstract

18 Pharmacokinetics from two randomised trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose rintonavir: The MaxCmin 1 & 2 Trials.
US Justesen, Z Fox, C Pedersen, P Cahn, J Gerstoft, N Clumeck, M Losso, B Peters, N Obel, A Castagna, UB Dragsted, and JD Lundgren on behalf of the MaxCmin 1 & 2 Trial groups.
Basic Clin Pharmacol Toxicol. 2007 Nov;101(5):339-44. abstract

20 The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. ZV Fox, AM Geretti, J Kjaer, UB Dragsted, AN Phillips, J Gerstoft, S Staszewski, B Clotet, V von Wyl, JD Lundgren.
AIDS. 2007 Oct 1;21(15):2033-42. abstract

21 HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. AN Phillips, C Sabin, D Pillay, JD Lundgren.
HIV Med. 2007 Nov;8(8):536-46. abstract

22 Dynamic use of procalcitonin in the intensive care unit. JU Jensen, L Hein, K Thornberg, J Loeken, H Tousi, KM Larsen, MH Andersen, M Bestle, T Mohr.
Int J Intensive Care. 2007;14(2):52-57

23 The Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA) and The ART Cohort Collaboration: Tuberculosis after Initiation of Antiretroviral Therapy in Low-Income and High-Income Countries. CID 2007;45:1518–1521.

24 The ART Cohort Collaboration: Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1 Infected Patients. Writing committee: Jonathan A C Sterne, Margaret May, Caroline Sabin, Andrew Phillips, Dominique Costagliola, Geneviève Chêne, Amy C Justice, Frank de Wolf, Robert Hogg, Manuel Battegay, Antonella D’Arminio Monforte, Norbert Schmeisser, Schlomo Staszewski, John Gill and Matthias Egger. J Acquir Immune Defic Syndr 2007; 46:607–615.

25 HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. Sterne JA, May M, Bucher HC, Ledergerber B, Furrer H, Cavassini M, Bernasconi E, Hirschel B, Egger M; Swiss HIV Cohort. J Intern Med 2007 261:255-67.

26 Visceral and subcutaneous adiposity measurements in adults: Influence of measurement site. Ellis KJ, Grund B, Visnegarwala F, Thackeray L, Miller CG, Chesson CE, El-Sadr W, and Carr A for the Strategies for Management of Anti-Retroviral Therapy (SMART) Study Group.
Obesity 2007; 15(6):1441-1447. article

Updated: 18 Oct 2010